To further its mission, NeurAegis has started the formation of a Board of Scientific Advisors (SAB) with the appointment of several distinguished academic and pharmaceutical scientists.
Dr. Bey has 45 years of experience in the biotechnology and pharmaceutical industry where he has participated in and led teams responsible for over 30 Investigational New Drug applications (INDs) in many therapeutic areas, including oncology, respiratory diseases, infectious diseases, inflammation, metabolic and central nervous system diseases. Dr. Bey served until October 2016 as Senior Vice President of R&D at Thrasos Therapeutics. Prior to joining Thrasos, Dr. Bey was the Chief Scientific Officer and Senior Vice President of R&D at ArQule. He also previously served as U.S. Senior Vice President of R&D at Hoechst Marion Roussel (HMR), now Sanofi.
Michael is a seasoned leader in the biotechnology and pharmaceutical industries with over 40 years' experience in leadership positions He currently serves as Director of Oculogics, Inc and is a Member of the Patent Review Board, Forsyth Dental Institute. In addition to these positions, he is the Head of R&D Diligence at Torrey Pines Investment and Senior R&D Diligence at ChemRar; Chief Scientific Officer at Amorsa Therapeutics, Inc., and the Chairman of the SAB and SVP Drug Development at Aminex Therapeutics, Inc. He also serves as Scientific Advisor for Avineuro,Inc., NeuroNascent, Inc., and Jasco Pharmaceuticals, Inc. Prior to entering the biotechnology industry in 1994 he was VP Research (North America) at the Marion Merrell Dow Research Institute.
Dr. Serge Bischoff spent over 43 years in medical and pharmaceutical research in neurosciences. He spent most of his professional life in the large pharma industry (Synthélabo-Sanofi, Ciba-Geigy, Novartis), where he was Head of various research programs for psychiatric, neurological and neurodegenerative diseases. Author of several patents and over hundred scientific publications and analysis articles, he is laureate of numerous awards including the Young Psychiatry Scientist Award by the Swiss Society of Psychiatry, the Leading Scientist Award at Novartis, the French National Contest of Creation of Innovative Enterprises, and very recently the World Contest of Innovation and the Valori Prize of the French Academy of Sciences.
Dr. Gary Lynch received his PhD at Princeton University and started his academic career at UC Irvine, where he contributed to make the Psychobiology Dept a World leader in neurosciences. For almost 50 years, his work has contributed to our understanding of the mechanisms of learning and memory, and more generally on how the brain processes information. He has published over 600 publications in top journals, has been invited to numerous Symposia and Meetings all over the World, and is the inventor on numerous patents. He was the co-founder of several companies, including Synaptics, Inc., Cortex Pharmaceuticals, Thorus, Inc, and Tensor, Inc. His vast knowledge in neurosciences and his experience in translating basic findings into therapeutic applications make him a terrific asset for NeurAegis.
Dr. Norton Peet is an International R&D Consultant, and provides guidance and direction to industrial and academic organizations on drug discovery and development strategies. Dr. Peet currently serves as the Chief Scientific Officer for Chicago BioSolutions, a newly formed drug discovery company. In prior positions, Dr. Peet was Head of Medicinal Chemistry at Microbiotix, where he designed the chemistry for all internal and external research proposals. Dr. Peet is an organic chemist by training (UNL, MIT) and has spent much of his career in big pharma, with the string of companies that led to Aventis (now Sanofi). When he left Aventis in 2000 he was Head of Medicinal Chemistry and Distinguished Scientist. He joined the executive team at ArQule as Vice President of Discovery Alliances, where he managed alliances with several companies and also built a multidisciplinary Drug Discovery Group. In 2002, he became the CEO of Aurigene Discovery Technologies, a drug discovery company, and built laboratories in Boston (Lexington) and Bangalore (India). Dr. Peet has authored 175 journal articles and 70 US patents, and has contributed to 25 awarded grant applications. He has organized numerous international symposia and serves on several editorial and scientific advisory boards.
Dr. Shujaath Mehdi is an expert in enzyme mechanisms and kinetics, in molecular aspects of drug design, discovery and development, and in translational medicine. Dr. Mehdi joined Merrell Dow (a predecessor company of Sanofi) in 1985 in Discovery Research after post-doctoral training in enzymology at Harvard University. Over the years he held the positions of Project Team Leader, Lab Head, and Group Leader of the Enzyme Chemistry group. Dr. Mehdi was instrumental in the design and characterization of enzyme inhibitors as drugs in multiple therapeutic areas. Prior to retirement, Dr. Mehdi led a cross-functional Translational Medicine group, whose responsibility was to apply translational principles to ensure the success of preclinical and clinical projects in the Immunoinflammation therapeutic area. After retirement from Sanofi in 2012 as a Distinguished Scientist, Dr. Mehdi has taught courses on ‘Drug Discovery Through Preclinical Development’ and on ‘Ethics of Science and Technology Management’ in the Master of Business and Science program at Rutgers University, and has lectured on Personalized Medicine at Rutgers and at Columbia University. He is the author of 50 publications, and is the co-inventor of 17 US Patents.